Immunotherapy dostarlimab (Jemperli) will be available on the NHS for patients with advanced primary or recurrent endometrial cancer after trial results showed that it can slow the spread of the cancer when added to chemotherapy.
The immunotherapy, which can provide patients with “significant extra time before their disease progresses” compared with …